Abstract
Background Key population HIV programmes in sub-Saharan Africa (SSA) require epidemiologic information to ensure equitable and equal access to services. We consolidated survey data among female sex workers (FSW), men-who-have-sex-with-men (MSM), people who inject drugs (PWID), and transgender people to estimate national-level key population size, HIV prevalence, and antiretroviral therapy (ART) coverage for mainland SSA.
Methods Key population size estimates (KPSE), HIV prevalence, and ART coverage data from 39 SSA countries between 2010-2022 were collated from existing databases and verified against source documents. We used Bayesian mixed-effects spatial regression to model urban KPSE as a proportion of the gender-matched 15-49 years adult population. We modelled subnational key population HIV prevalence and ART coverage with age/gender/year/province-matched total population estimates as predictors.
Findings We extracted 2062 unique KPSE, 1243 HIV prevalence, and 201 ART coverage data points. Across national urban populations, a median of 1.71% of women were FSW (interquartile range [IQR]=1.21-1.97%); 0.92% of men were MSM (IQR=0.73-1.01%); 0.32% of men injected drugs (IQR=0.28-0.39%), and 0.14% of women were transgender (IQR=0.12-0.17%). Key population HIV prevalence was 4 to 6 times higher than gender-matched total population prevalence. ART coverage was correlated with, but lower than, total population ART coverage. Across SSA, key populations were estimated as 1.3% (95%CI: 0.9-1.7%) of the total population aged 15-49 years but 6.3% (4.6-8.6%) of people living with HIV.
Interpretation Key populations in SSA experience disproportionately higher HIV burden and lower ART coverage, underscoring a need for focused prevention and treatment services. However, data availability and heterogeneity limit precise estimates for programming and monitoring trends. Strengthening key population surveys and routine data within national HIV strategic information systems would support more precise estimates.
Funding UNAIDS, BMGF, NIH
Evidence before this study Key populations, including female sex workers (FSW), men who have sex with men (MSM), people who inject drugs (PWID), and transgender populations, are at high risk of HIV globally, including in sub-Saharan Africa (SSA). Delivering appropriate HIV prevention and treatment programming to these populations, and monitoring attainment of an equitable HIV response, requires robust information on key population size, HIV prevalence, the treatment cascade, and new HIV infections. For this reason, key population surveys, including population size estimation and bio-behavioural surveys, are a standard component of a comprehensive national HIV surveillance portfolio.
Several complementary ongoing initiatives consolidate HIV data on key populations to support programme planning and implementation, global advocacy, and research. These include the Key Population Atlas and Global AIDS Monitoring (Joint United Nations Programme on HIV/AIDS [UNAIDS]), databases maintained by the US Centers for Disease Control and Prevention (CDC) and the Global Fund Against TB, AIDS, and Malaria (The Global Fund), and the Global.HIV initiative (Johns Hopkins University). These include similar data sources, but vary in scope, inclusion criteria, data elements recorded, and linkage to and validation against primary source data sets and reports. Incomplete recording of key methodological details limits appraisal and formal evidence synthesis, and therefore utility of data for strategic planning.
Many other research studies have systematically reviewed, analysed, and extrapolated key population survey data in sub-Saharan Africa in single countries or across multiple countries. These studies have tended to focus on specific outcomes or population groups of interest, and primarily comprise an appraisal of peer-reviewed literature.
Added value of this study We consolidated and deduplicated data collected between 2010-2022 from existing key population surveillance databases maintained by the UNAIDS Key Population Atlas, UNAIDS Global AIDS Monitoring, US CDC, and the Global Fund. We used the Johns Hopkins University Global.HIV repository of surveillance reports, additional web-based searches, and engagement with country HIV strategic information teams to obtain survey reports in the peer-reviewed and grey literature, and validated each observation of key population size, HIV prevalence, or ART coverage against primary surveillance reports. We used regression analyses to characterise the relationship between key population and total population HIV indicators and extrapolated key population size estimates (KPSE), HIV prevalence, and ART coverage data to national-level estimates for all countries in mainland SSA.
This exercise was the most comprehensive effort to date to consolidate key population HIV data in SSA. We analysed 114 KPSE, 198 HIV prevalence, and 56 ART coverage studies. We estimated that across urban populations in SSA countries aged 15-49, a median of 1.71% of women were FSW; 0.92% of men have sex with men; 0.32% of men injected drugs; and 0.14% of women were transgender. This translated to 3.4 million FSW, 2 million MSM, 870,000 PWID, and 380,000 transgender women (TGW) in SSA who require comprehensive HIV prevention or treatment services. FSW, MSM, PWID, and TGW combined were estimated as 1.3% of the population aged 15-49, but comprised 6.3% of people living with HIV. ART coverage among members of key populations living with HIV increased with total population ART coverage, but was lower for all key populations. We identified large gaps in data availability. Of the four key populations and three indicators studied, only Mozambique had data for all twelve indicators. Data were particularly sparse for transgender populations and PWID.
Implications of all the available evidence Key populations experience HIV prevalence and lower ART coverage across all settings in sub-Saharan Africa than the total population. Extrapolated national estimates provide a foundation for planning appropriate key population-focused services for HIV prevention and treatment in all settings, including those with no or limited data.
However, large data availability gaps, inconsistency of existing data, and consequent wide uncertainty ranges around estimates limit the ability of existing data to guide granular programmatic planning and target setting for key population services and to monitor trends. More consistent surveillance implementation and improved routine surveillance through HIV prevention and treatment programmes for key populations would support monitoring equitable and equal programme access, as outlined in the Global AIDS Strategy 2021-2026 to end HIV/AIDS as a public health threat by 2030.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by UNAIDS, Bill and Melinda Gates Foundation (INV-006733), National Institute of Allergy and Infectious Disease of the National Institutes of Health under award number R01AI136664, and the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. MM-G's research program is funded by a Canada Research Chair (Tier II) in Population Health Modeling.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Source data were publicly available and included as supplementary file in submission
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
- Added data made available July 2022-November 2023 - Included estimates for transgender women
Data Availability
All survey data produced in the present work are contained in the supplementary materials All remaining data are available upon reasonable request to the authors
